Logo image of ATAI

ATAI BECKLEY NV (ATAI) Stock Price, Forecast & Analysis

USA - NASDAQ:ATAI - NL0015000DX5 - Common Stock

4.592 USD
+0.23 (+5.32%)
Last: 11/10/2025, 10:13:08 AM

ATAI Key Statistics, Chart & Performance

Key Statistics
Market Cap1.08B
Revenue(TTM)308.00K
Net Income(TTM)-149.27M
Shares235.97M
Float216.81M
52 Week High6.75
52 Week Low1.15
Yearly DividendN/A
Dividend YieldN/A
EPS(TTM)-0.69
PEN/A
Fwd PEN/A
Earnings (Next)11-11 2025-11-11/bmo
IPO2021-06-18
Sector
GICS SectorHealth Care
GICS IndustryPharmaceuticals
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS SubIndustryPharmaceuticals


ATAI short term performance overview.The bars show the price performance of ATAI in the last week, last 2 weeks, last month, last 3 and 6 months. 1 week 2 week 1 month 3 months 6 months 0 50 100 150 200

ATAI long term performance overview.The bars show the price performance of ATAI in the last 1, 2 and 3 years. 1 year 2 years 3 years 100 200 300

The current stock price of ATAI is 4.592 USD. In the past month the price decreased by -14.51%. In the past year, price increased by 209.22%.

ATAI BECKLEY NV / ATAI Daily stock chart

ATAI Latest News, Press Relases and Analysis

ATAI Competitors/Peers

The largest stocks on the US markets in the "Pharmaceuticals" sub-industry
Full List
Symbol
Company Name
TA
FA
PE
Market Cap
LLY ELI LILLY & CO44.61928.54B
JNJ JOHNSON & JOHNSON18.02450.41B
MRK MERCK & CO. INC.9.83216.22B
PFE PFIZER INC7.69139.88B
BMY BRISTOL-MYERS SQUIBB CO7.1795.73B
ZTS ZOETIS INC1953.39B
RPRX ROYALTY PHARMA PLC- CL A9.5222.83B
VTRS VIATRIS INC4.3311.77B
ELAN ELANCO ANIMAL HEALTH INC23.2411.09B
CORT CORCEPT THERAPEUTICS INC83.547.75B
AXSM AXSOME THERAPEUTICS INCN/A6.97B
LGND LIGAND PHARMACEUTICALS28.114.02B

About ATAI

Company Profile

ATAI logo image ATAI Life Sciences NV is a clinical-stage biopharmaceutical company. The company is headquartered in Amstelveen, Noord-Holland and currently employs 54 full-time employees. The company went IPO on 2021-06-18. The firm focused on developing treatments for mental health disorders. The firm's pipeline includes psychedelic and non-psychedelic compounds targeting depression, anxiety, and other unmet needs in psychiatry.

Company Info

ATAI BECKLEY NV

Prof. J.H.Bavincklaan 7

Amstelveen NOORD-HOLLAND 100022 NL

CEO: Florian Brand

Employees: 54

ATAI Company Website

ATAI Investor Relations

Phone: 31207932536

ATAI BECKLEY NV / ATAI FAQ

What does ATAI do?

ATAI Life Sciences NV is a clinical-stage biopharmaceutical company. The company is headquartered in Amstelveen, Noord-Holland and currently employs 54 full-time employees. The company went IPO on 2021-06-18. The firm focused on developing treatments for mental health disorders. The firm's pipeline includes psychedelic and non-psychedelic compounds targeting depression, anxiety, and other unmet needs in psychiatry.


What is the current price of ATAI stock?

The current stock price of ATAI is 4.592 USD. The price increased by 5.32% in the last trading session.


Does ATAI stock pay dividends?

ATAI does not pay a dividend.


How is the ChartMill rating for ATAI BECKLEY NV?

ATAI has a ChartMill Technical rating of 5 out of 10 and a ChartMill Fundamental rating of 3 out of 10.


How is the market expecting ATAI stock to perform?

17 analysts have analysed ATAI and the average price target is 12.35 USD. This implies a price increase of 169.02% is expected in the next year compared to the current price of 4.592.


How is the valuation of ATAI BECKLEY NV (ATAI) based on its PE ratio?

ATAI BECKLEY NV (ATAI) does not have a PE ratio as the earnings reported over the last twelve months were negative (-0.69).


Can you provide the growth outlook for ATAI BECKLEY NV?

The Revenue of ATAI BECKLEY NV (ATAI) is expected to grow by 355.42% in the next year. Check the estimates tab for more information on the EPS, Sales, EBIT and EBITDA future analyst estimates.


ATAI Technical Analysis

ChartMill assigns a technical rating of 5 / 10 to ATAI. When comparing the yearly performance of all stocks, ATAI is one of the better performing stocks in the market, outperforming 97.13% of all stocks.


Chartmill TA Rating
Chartmill Setup Rating

ATAI Fundamental Analysis

ChartMill assigns a fundamental rating of 3 / 10 to ATAI. While ATAI has a great health rating, there are worries on its profitability.


Chartmill FA Analysis
Valuation
Growth
Profitability
Health
Dividend

ATAI Financial Highlights

Over the last trailing twelve months ATAI reported a non-GAAP Earnings per Share(EPS) of -0.69. The EPS decreased by -72.5% compared to the year before.


Industry RankSector Rank
PM (TTM) N/A
ROA -78.89%
ROE -103.85%
Debt/Equity 0
Chartmill High Growth Momentum
EPS Q2Q%61.11%
Sales Q2Q%163.37%
EPS 1Y (TTM)-72.5%
Revenue 1Y (TTM)-1.91%

ATAI Forecast & Estimates

17 analysts have analysed ATAI and the average price target is 12.35 USD. This implies a price increase of 169.02% is expected in the next year compared to the current price of 4.592.

For the next year, analysts expect an EPS growth of 45.22% and a revenue growth 355.42% for ATAI


Analysts
Analysts83.53
Price Target12.35 (168.95%)
EPS Next Y45.22%
Revenue Next Year355.42%

ATAI Ownership

Ownership
Inst Owners13.93%
Ins Owners2.66%
Short Float %7.44%
Short Ratio2.57